Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism

This study will evaluate, if testosterone enanthate administered subcutaneously once each
week by an auto-injector to men with low testosterone, can raise their levels into the normal
range.

The study will investigate the ability to adjust testosterone enanthate dose levels using
single point blood concentrations.

Safety and tolerability of testosterone administration will be evaluated along with the
patient's ability to use the auto-injector and follow the instructions for auto-injector use.

Inclusion Criteria:

- Adult males aged ≥ 18 year of age with a documented diagnosis of hypogonadism

- Total testosterone levels < 300 ng/dL at two qualification visits

- Patients in good general health

Exclusion Criteria:

- Allergy to sesame or testosterone products

- BMI ≥ 40 kg/m2

- Hematocrit ≥ 52%

- History or current evidence of breast or prostate cancer

- Elevated PSA (Prostate-Specific Antigen) for age.

- Abnormal DRE (digital rectal examination)

- Obstructive uropathy of prostatic origin

- Poorly controlled diabetes

- Congestive heart failure

- Within 6 months of screening, MI (myocardial ischemia), unstable angina leading to
hospitalization, percutaneous coronary intervention, coronary artery bypass graft,
uncontrolled cardiac arrhythmia, stroke transient ischemia attack, ceratoid
revascularization, endovascular procedure, or surgical intervention for peripheral
vascular disease.

- History or current treatment of thromboembolic disease.

- Use of ACTH (adrenocorticotropic hormone) or oral/depot corticosteroids within 6 weeks
of screening.

- History of severe, untreated sleep apnea

- Subjects with any clinically significant medical condition which, in the opinion of
the investigator, would make the subject an unsuitable candidate for enrollment in the
study

- Positive serology for HIV, hepatitis B or hepatitis C

- Current evidence of drug or alcohol abuse.

- Skin conditions in injection site that could confound injection site assessments.

- Administration of other investigational compounds within one month of screening or 5
half-lives of the investigational compound, whichever is longer).

- Use of estrogen, GnRH (gonadotropin-releasing hormone) or growth hormone within 12
months of screening.

- Use of other androgens (DHEA(Dehydroepiandrosterone), anabolic steroids, other sex
hormones) or other substances/supplements know to affect the PK (pharmacokinetics) of
testosterone enanthate

- Considered or scheduled surgical or dental procedures associated with blood loss ≥500
mL during study.

- Donation of plasma or blood within 56 days of screening or history of donation of > 50
mL of blood or plasma within 3 months of screening.

- Donation of plasma or blood during study